Publications

1. Position of the National Health Care Institute on nivolumab (Opdivo®) for the treatment of dMMR- of MSI tumors

   The National Health Care Institute concludes that nivolumab (Opdivo®) for the treatment of certain patients with locally advanced ...

   Report | 23-06-2022

2. GVS advice elexacaftor/tezacaftor/ivacaftor (Kaftrio®) in combination with ivacaftor (Kalydeco®): extension of further conditions

   The National Health Care Institute advises the Minister to include cenobamate (Ontozry®) in List 1A of the GVS. Cenobamate is ...

   Report | 20-06-2022

3. Implementation of the European health technology assessment legislation (EU HTAR)

   The National Health Care Institute is preparing for new European health technology assessment legislation which is going to be ...

   Publication | 01-06-2022

4. GVS advice bupropion in combination with naltrexone (Mysimba®)

   The National Health Care Institute advises the Minister to include bupropion in combination with naltrexone (Mysimba®) in the ...

   Report | 17-05-2022

5. GVS advice GLP-1 receptor agonists extension further conditions

   The National Health Care Institute advises the Minister to extend the reimbursement conditions for dulaglutide, exenatide, ...

   Report | 16-05-2022

6. GVS advice to not include pitolisant (Ozawade®)

   The National Health Care Institute has completed its assessment whether pitolisant (Ozawade®) can be included in the Medicine ...

   Report | 10-05-2022

7. Package advice vitamin D

   The National Health Care Institute recommends that all colecalciferol-containing medicinal products and calcifediol be removed ...

   Report | 09-05-2022

8. Package advice on zanubrutinib (Brukinsa®) for the treatment of Waldenström macroglobulinaemia (WM)

   The National Health Care Institute advises the Minister to include zanubrutinib (Brukinsa®) in the basic health insurance package ...

   Report | 27-04-2022

9. GVS advice on dabigatran etexilate (Pradaxa®) capsules extension further conditions

   The National Health Care Institute advises the Minister to amend List 2 of the GVS to extend the reimbursement of dabigatran ...

   Report | 25-04-2022

10. International strategic agenda 2022-2023 National Health Care Institute

    The international strategic agenda 2022-2023 describes the international activities of the National Health Care Institute ...

    Publication | 21-04-2022